Europe ADHD Therapeutics Market

Europe ADHD Therapeutics Market Size (2022 to 2027)

As per our report, the size of the ADHD Therapeutics Market in Europe is predicted to be worth USD 4.68 billion by 2027 from USD 3.17 billion in 2022, growing at a CAGR of 8.10% during the forecast period.

The growing prevalence of ADHD in children and adults is the primary driver of the ADHD therapeutics market in the European region. Associated mental health problems include depression, anxiety disorders, and learning disabilities are also associated with the diagnosis of ADHD. The rising prevalence is between 3% and 8% across Europe. In addition, around 10% of children have been early-on diagnosed with difficulty with inattention, impulsivity, delayed learning that are often misdiagnosed with ADHD.

The number of children born each year in England is currently around 705,000. ADHD affects about 4-7% of children and 4-5% of adults and is more common in men than women. Nearly 5.5% of children and adolescents were diagnosed with ADHD in Germany in the year 2019. In addition, 1 in 4 people will experience some mental health problem every year in the U.K. 2 in 8 people were reported having a common mental health problem such as anxiety and depression during a study. According to a national survey in the U.K, ADHD prevalence has increased each year; around 11,000 children were newly diagnosed. The U.K spends over £ 1.22 billion each year on ADHD diagnosis and therapeutics, especially on children and adolescents. Most adults do not receive treatment, as they are often undiagnosed, and untreated ADHD leads to disorganized lives or using other options such as non-prescription drugs or alcohol as a coping mechanism. 

The increase in product approvals, clinical trials, and new research camps for ADHD awareness is expected to create significant growth opportunities for the market. Parent training can improve several behavioral problems, create much-needed awareness for the detection of ADHD as well. The UK national institute for health and care Excellence dictates the use of drugs only in severe cases of children, although the drugs are the first-line treatment for adults. ADHD therapeutics not only drugs but also psychosomatic therapies, namely behavioral therapeutics, cognitive therapeutics, relationship education, early intervention in schools, family therapeutics, social skills training, etc. to for the treatment of ADHD. All these factors mentioned above are predicted to favor the progress of the European ADHD therapeutics market during the forecast period.  

On the other hand, ADHD therapeutics require many clinical trials, variety of drugs options, from CNS systemic drugs to antipsychotic drugs, which increase the overall cost of treatments. These factors are the major impediments to market growth. Furthermore, most often, ADHD is misdiagnosed in children. In addition, the limited availability of certain drugs is expected to have a negative effect on the market. Therefore, these factors are forecasted to hamper the growth rate of the market during the forecast period.

This research report on the Europe ADHD Therapeutics Market has been segmented and sub-segmented into the following categories:

By Medication:

• Stimulants
• Non-Stimulants

By Psychotherapy:

• Behaviour Therapy
• Cognitive Behavioural Therapy
• Interpersonal Psychotherapy
• Family Therapy

By Education Or Training:

• Parent Management Training
• Social Skills Training
• School-Based Interventions

By Country:

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

The United Kingdom ranks second in the European ADHD therapeutics market, closely following the French market. The ADHD therapeutics market in the U.K is expected to grow at a substantial CAGR of 4.5% during the review period. The penetration of excellent health insurance and the availability of new treatment modalities are driving the market growth in the region.

Significant technological advancements, increase in healthcare expenditure, growing prevalence of mental disorders, and meatal healthcare awareness are the key factors driving the market's growth.

The ADHD therapeutics market in France and Germany is emerging as a rapidly growing market in the European region. The improved economies of the area with stimulating the health infrastructure are leading to the development of new therapies for ADHD, boosting the growth of the regional markets. In addition, increased financial support from the public and private sectors and the booming pharmaceutical industry support the development of these regional markets.

KEY MARKET PLAYERS:

A few of the promising companies operating in the European ADHD therapeutics market profiled in this report are Shire plc (Ireland), Neos Therapeutics, Inc. (U.S.), Eli Lilly and Company (U.S.), Pfizer Inc. (U.S.), Alcobra Ltd. (Israel), Supernus Pharmaceuticals, Inc. (U.S.), Noven Pharmaceuticals, Inc. (U.S.), Novartis AG (Switzerland), Johnson & Johnson (U.S.) and Curemark, LLC. (U.S.).